

24 February 2026

Non-Executive Board Changes

AstraZeneca PLC announced today that Non-Executive Director Nazneen Rahman will retire from the Board having joined in 2017. This will take effect at the conclusion of the Company's AGM on 9 April 2026.

The Company also announced today that at the conclusion of the Company's AGM on 9 April 2026:

- Tony Mok will succeed Nazneen Rahman as Chair of the Sustainability Committee and become a member of the Nomination and Governance Committee; and
- Birgit Conix will become a member of the Sustainability Committee.

Michel Demaré, Chair of AstraZeneca, said "On behalf of the whole Board, I would like to thank Nazneen Rahman for the significant contributions she has made to our work as a Board, as well as the insights, experience and leadership she brought to our Board Committees. Nazneen has been with us since 2017 and we have benefited from her specialist experience in genetics research and translation, sustainable healthcare as well as her passion for open science and science communication. Nazneen has been a member of the Science Committee throughout her tenure, chairing it from 2017 to 2023, and has been Chair of the Sustainability Committee since its establishment in 2021. She has also served on the Remuneration Committee and Nomination and Governance Committees."

[AstraZeneca](#)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](https://www.astrazeneca.com) and follow the Company on Social Media [@AstraZeneca](#).

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Matthew Bowden
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOASEDFUDEMSEDE